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ABSTRACT
Precision medicine uses individually determined 
genomic information to guide treatment in cancer and other 
diseases. We have implemented a clinical genomics assay 
that uses targeted next-generation sequencing of 25 cancer-
related genes to guide the use of targeted therapies in diverse 
malignancies. We report the case of a 55-year-old woman 
with a poorly differentiated squamous cell carcinoma of thy-
mic origin, with disease progression after standard treatment. 
Targeted tumor sequencing revealed the presence of a KIT 
codon 579 deletion (p.D579del). This specific mutation has 
not previously been associated with thymic tumors, but has 
been reported in gastrointestinal stromal tumors and has been 
associated with response to imatinib. Imatinib therapy was 
instituted for and resulted in stabilization of disease. This case 
illustrates the potential of clinical next-generation sequenc-
ing to open unexpected avenues for treatment and thereby 
improve patient outcomes.
INTRODUCTION
Although standard therapies exist for many malignancies, 
there is increasing interest in using individually determined 
genetic information to guide cancer therapy. This is especially 
true in treatment-refractory cases for which standard options 
have failed. Clinical next-generation sequencing (NGS) makes 
it possible to use genetic variants present in the tumor to guide 
the selection of targeted therapies. Although data from prospec-
tive clinical trials may guide use of a given therapy in patients 
with certain defined genetic lesions (for example, EML4-ALK 
rearrangement is used to triage lung cancer patients for crizo-
tinib therapy),1 in other instances mutations that are novel or 
atypical for a given tumor may suggest the use of a therapy 
that would not otherwise have been considered (e.g., a tyrosine 
kinase inhibitor [TKI] for a mucosal melanoma).2
We present a case of a poorly differentiated thymic car-
cinoma in which clinical NGS revealed a therapeutic target. 
Therapy directed against the target mutation resulted in stabi-
lization of previously progressive disease.
MATERIALS AND METHODS
Targeted NGS
For this case, Genomics and Pathology Services at 
Washington University (GPS@WUSTL) performed targeted 
NGS of 25 cancer-related genes (all exons of BRAF, CHIC2, 
CSF1R, CTNNB1, DNMT3A, EGFR, FLT3, IDH1, IDH2, 
JAK2, KIT, KRAS, MAP2K2, MAPK1, MET, NPM1, NRAS, 
PDGFRA, PIK3CA, PTEN, PTPN11, RET, RUNX1, TP53, 
and WT1) using DNA extracted from formalin-fixed, paraffin-
embedded tumor tissue. The assay used Agilent SureSelect 
capture followed by Illumina HiSeq 2000 sequencing. GPS@
WUSTL is accredited by the College of American Pathologists 
and certified under the Clinical Laboratory Improvement 
Amendments.
Regulatory Compliance
The institutional review board at Washington University 
determined that the present report does not constitute human 
research. The patient consented to the publication of this 
case report.
CASE REPORT
The patient was a 55-year-old woman with a poorly dif-
ferentiated thymic carcinoma, metastatic to the liver (Fig. 1). 
Computed tomography (CT) scan showed a 2.3 × 2.0 cm ante-
rior mediastinal mass, two liver lesions measuring 4.3 and 
1.6 cm, and two indeterminate nodules in the right lung, 5 
and 6 mm in diameter. Fluorodeoxyglucose positron emission 
tomography showed increased tracer uptake in the mediasti-
nal and liver lesions. A CT-guided core biopsy and fine-nee-
dle aspiration were performed on the largest liver lesion and 
showed a poorly differentiated squamous cell carcinoma, pre-
sumed to be of thymic origin.
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/14/0902-0e12
Stabilization of Disease after Targeted Therapy in a 
Thymic Carcinoma with KIT Mutation Detected by Clinical 
Next-Generation Sequencing
Ian S. Hagemann, MD, PhD,* Ramaswamy Govindan, MD,† Cylen Javidan-Nejad, MD,‡  
John D. Pfeifer, MD, PhD,* and Catherine E. Cottrell, PhD, FACMG*
*Genomics and Pathology Services, Department of Pathology and 
Immunology, †Section of Medical Oncology, Department of Medicine, 
and ‡Mallinckrodt Institute of Radiology, Washington University, 
St. Louis, Missouri.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Catherine E. Cottrell, PhD, FACMG, 660 
S. Euclid Avenue, Campus Box 8118, St. Louis, MO 63110. E-mail: 
ccottrell@path.wustl.edu
xxxxxxXXX
CASE REPORT
e13Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 2, February 2014 Stabilization of Disease after Targeted Therapy
The patient was initially treated with four cycles of pacli-
taxel and carboplatin, with resulting decrease in the diameter 
of the lung nodules and 50% decrease in the diameter of one 
liver lesion. She received one additional cycle, at which point 
the regimen was discontinued because of neurotoxicity. At 4 
months postcompletion, minimal increase in size of one liver 
lesion was noted. Single-agent pemetrexed was initiated; after 
two cycles of therapy, continued progression was noted in the 
liver and therapy was changed to single-agent gemcitabine. 
After six cycles of therapy, the patient began to experience pain 
in the right upper quadrant of the abdomen. This pain was con-
sidered to be related to the liver lesions. Transarterial chemoem-
bolization (TACE) of the dominant liver lesions was therefore 
performed using beads loaded with 50 mg of gemcitabine. At 1 
month post TACE, CT evidence of tumor necrosis was noted. 
However, at 3 months post TACE, new metastases were seen in 
liver segment 5, including one along the anterior margin of the 
treated lesion; several other new lesions were seen throughout 
the liver. Throughout the patient’s course to this point, the lung 
and mediastinal lesions were stable.
At the time of gemcitabine initiation, the decision was 
made to send tissue from the liver lesion for NGS of a set of 
genes in which somatic variation is known to be associated 
with response to targeted therapy. The neoplastic cellularity of 
the available tissue was estimated at 67%. Paraffin-embedded 
tissue cores yielded 4.3 µg of DNA; 1 µg was used for library 
preparation. Sequencing yielded more than 63 million paired-
end 101 base pair reads, of which more than 13 million were 
mapped uniquely to the capture region, giving a mean cover-
age of more than 3000-fold. Coverage of more than 50-fold 
was obtained for 98.7% of targeted positions.
The NGS data revealed a deletion of three nucleotides in 
the KIT gene (c.1735_1737delATG), resulting in a p.D579del 
coding region change in exon 11 (Fig. 2A). The mutation was 
confirmed by Sanger sequencing (Fig. 2B). Molecular mod-
eling confirmed that the mutation was located in the juxta-
membrane domain of the receptor (Fig. 2C), which has an 
autoinhibitory function.3
Given the presence of a potentially actionable KIT muta-
tion, and the patient’s progression of disease through multiple 
chemotherapeutic agents, the patient was started on 400 mg 
imatinib per day. After 3 months of imatinib therapy, CT 
scan showed stable disease by Response Evaluation Criteria 
in Solid Tumors (RECIST), with a 20% decrease in the sum 
of longest diameters of the target lesions (thymic lesion 
4.2 → 3.7 cm, Fig. 3A–B; liver lesion 4.5 → 3.5 cm; lung 
nodule 0.7 → 0.4 cm). A repeat bone scan was negative for 
osseous metastases. CT scan at 5 months showed cystification 
of the mediastinal mass, further decreased size of one lung 
nodule, and stable disease in the liver. A CT scan at 7 months 
from initiation of imatinib continued to show stable disease. 
The patient was alive with stable disease by RECIST criteria 
(Fig. 3C) at last follow-up, 23 months after diagnosis and 12 
months after initiation of NGS-directed targeted therapy.
DISCUSSION
The patient reported here presented with a poorly differen-
tiated thymic carcinoma that proved refractory to standard 
cytotoxic chemotherapy regimens. Thymic carcinoma is rela-
tively rare, so the number of trials reported is small in com-
parison to other more common malignancies, and therapies 
in the past have been determined empirically.4,5 In addition 
to nontargeted chemo- and radiotherapy, there is evidence 
to suggest the use of targeted therapies; specifically, thymic 
tumors have been found to carry mutations in and/or over-
express KRAS,6 KIT, EGFR, IGF1R, and VEGF.7 Given the 
diversity of molecular aberrations that can be found, some 
authors have advocated that molecular profiling be used rou-
tinely for this tumor type.4
Clinical targeted NGS was used to guide therapy in 
this treatment-refractory malignancy. Sequencing identified 
an in-frame deletion of three nucleotides in the juxtamem-
brane domain (exon 11) of the KIT receptor. KIT encodes 
a receptor tyrosine kinase, which is often mutated in gas-
trointestinal stromal tumors (GISTs)8 and represents a tar-
get for therapeutic inhibition by various semiselective TKIs 
FIGURE 1.  Histopathology of the patient’s poorly differentiated thymic carcinoma metastatic to the liver, submitted for clinical 
next-generation sequencing. A, Hematoxylin-eosin, 200×; (B) Cytokeratin 5/6 immunostain, 200×.
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including imatinib and sunitinib.9 Thymic carcinomas, too, 
have occasionally been found to harbor KIT mutations.10 In 
one series of seven cases, two had KIT mutations6; another 
report estimated the prevalence of KIT mutation in thymic 
carcinoma at 9%.4 The mutations are diverse and a sequenc-
ing-based approach is necessary to comprehensively identify 
them (Table 1).
Moreover, KIT mutations predict the effectiveness of 
TKI therapy in both GIST and thymic carcinoma. In GIST, 
mutations in the juxtamembrane domain, including p.D579del 
specifically, are known to confer sensitivity to imatinib.11,12 In 
one series, patients with GIST harboring KIT exon 11 muta-
tions showed a partial response to imatinib in 83.5% of cases, 
whereas no patient with wild-type KIT showed a response.13 In 
thymic carcinoma, several different KIT mutations have been 
associated with sensitivity to TKIs (Table 1). Most notably, 
a three-codon in-frame deletion, p.P577–D579del, similar to 
the one identified in our patient, was discovered in one patient 
using research (nonclinical) testing and was associated with 
response to sorafenib.14
Although a majority of thymic carcinomas express 
KIT,15 immunoreactivity alone does not seem to correlate 
with imatinib susceptibility.16,17 A phase 2 trial of imatinib in 
unselected thymic carcinomas also failed to show a benefit.26 
These observations underline the importance of mutation test-
ing in patient selection.
FIGURE 2.  Molecular evidence for a single-codon KIT deletion. A, In-frame deletion of three nucleotides in exon 11 of KIT as 
visualized in the Integrative Genomics Viewer.24 B, Electropherogram from confirmatory Sanger sequencing, showing reference 
trace (top) and patient sample (bottom). C, Ribbon diagram of juxtamembrane and tyrosine kinase domains of KIT receptor, 
residues 565–933. The deleted residue (Asp579) and a bound imatinib molecule (STI-571) are shown as stick figures. Drawn 
from PDB entry 1T463 using the SwissPDB Viewer.25
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KIT p.D579del has occasionally been identified as a 
germline change in patients with an inherited predisposition 
to GIST.12,18 Because nontumor tissue was not sequenced for 
the present patient, it is not possible to fully exclude the pos-
sibility that this was a germline variant, but the patient did not 
have a personal or family history of GIST.
In conclusion, we report here a case of treatment-refrac-
tory thymic carcinoma in which targeted tumor NGS provided 
guidance for salvage therapy. The tumor was found to harbor 
KIT p.D579del, a mutation that has previously been associated 
with susceptibility to TKIs. Treatment with imatinib resulted 
in stabilization of the patient’s disease. Patients such as this 
one show that clinical NGS has the potential to guide therapy 
in clinical oncology.
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